{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-010345","form_type":"8-K","ticker":"PAHC","cik":"0001069899","company_name":"PHIBRO ANIMAL HEALTH CORP","filed_at":"2026-02-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.496322+00:00","generated_at":"2026-05-16T04:48:05.514268+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Phibro Q2 net sales up 21% to $374M; raises FY2026 guidance","bullets":["Net sales $373.9M (+21% YoY); net income $27.5M vs $3.2M; diluted EPS $0.67 vs $0.08.","Adjusted diluted EPS $0.87 (+58% YoY); adjusted EBITDA $68.1M (+41% YoY).","Animal Health sales +26% to $290M, driven by $57.5M incremental MFA portfolio revenue.","FY2026 guidance raised: net sales $1.45-1.50B, adjusted EBITDA $245-255M, adjusted EPS $2.93-3.10.","Gross margin improved 260 bps to 35.5%; 3.1x gross leverage ratio; free cash flow $47.3M TTM."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-010345","json":"https://secwatch.observer/filing/0001104659-26-010345.json","markdown":"https://secwatch.observer/filing/0001104659-26-010345.md","text":"https://secwatch.observer/filing/0001104659-26-010345.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1069899/000110465926010345/0001104659-26-010345-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1069899/000110465926010345/pahc-20260204x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T04:48:05.514268+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}